Liven Pharmaceuticals Limited (PSX:LIVEN)

Liven Pharmaceuticals Income Statement

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cost of Revenue	71.74	-	-	-	-	0.32
Gross Profit	34.29	-	-	-	-	-0.32
Selling, General & Admin	18.76	2	2.12	2.95	2.1	1.85
Other Operating Expenses	-	-	-	-	-	17.84
Operating Expenses	30.55	13.79	15.22	17.51	18.19	19.69
Operating Income	3.75	-13.79	-15.22	-17.51	-18.19	-20.01
Interest Expense	-0	-	-	-	-	-
Other Non Operating Income (Expenses)	119.3	-	-0	-0	-0	-0
EBT Excluding Unusual Items	123.04	-13.79	-15.23	-17.51	-18.19	-20.02
Pretax Income	123.04	-13.79	-15.23	-17.51	-18.19	-20.02
Income Tax Expense	9.4	-2.61	-2.9	-3.22	-3.55	-3.09
Net Income	113.64	-11.18	-12.33	-14.29	-14.63	-16.93
Net Income to Common	113.64	-11.18	-12.33	-14.29	-14.63	-16.93
Shares Outstanding (Basic)	30	12	12	12	12	12
Shares Outstanding (Diluted)	30	12	12	12	12	12
EPS (Basic)	3.75	-0.92	-1.02	-1.18	-1.21	-1.40
EPS (Diluted)	3.75	-0.92	-1.02	-1.18	-1.21	-1.40
EBITDA	19.68	-2	-2.12	-2.95	-2.1	-2.14
D&A For EBITDA	15.93	11.79	13.1	14.56	16.08	17.87
EBIT	3.75	-13.79	-15.22	-17.51	-18.19	-20.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.